secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001171843-26-003153
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M
--------------------------------------------------------------------------------

- Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.
- Raised $345M gross in April 2026 public offering; cash at March 31, 2026 was $451.5M, supplemented by ~$323.9M net proceeds.
- Q1 2026 net loss $78.7M ($1.18/share) vs $53.8M ($0.81) in Q1 2025; R&D expenses $73M, up from $52.6M.
- Phase 1 CDX-622 proof-of-mechanism study in asthma ongoing; Phase 2 PN data summer 2026, AD data late 2026.
- Revenue $0 in Q1 2026 (vs $0.7M); management expects cash to fund operations through 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/0001171843-26-003153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184326003153/f8k_050726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer